KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Revenue (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Revenue readings, the most recent being $168.4 million for Q4 2025.

  • On a quarterly basis, Revenue rose 143.73% to $168.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $403.1 million, a 21.31% increase, with the full-year FY2025 number at $403.1 million, up 21.31% from a year prior.
  • Revenue hit $168.4 million in Q4 2025 for Esperion Therapeutics, up from $87.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $168.4 million in Q4 2025 to a low of $8.0 million in Q1 2021.
  • Median Revenue over the past 5 years was $33.1 million (2023), compared with a mean of $50.3 million.
  • Biggest five-year swings in Revenue: tumbled 80.84% in 2021 and later skyrocketed 466.14% in 2024.
  • Esperion Therapeutics' Revenue stood at $15.4 million in 2021, then rose by 22.19% to $18.8 million in 2022, then soared by 71.38% to $32.2 million in 2023, then surged by 114.3% to $69.1 million in 2024, then surged by 143.73% to $168.4 million in 2025.
  • The last three reported values for Revenue were $168.4 million (Q4 2025), $87.3 million (Q3 2025), and $82.4 million (Q2 2025) per Business Quant data.